MAP2K1
Top View
- Leveraging Systematic Functional Analysis to Benchmark an in Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer
- Mir-181A Down-Regulates MAP2K1 to Enhance Adriamycin Sensitivity in Leukemia HL-60 Cells
- Kinome Expression Profiling to Target New Therapeutic Avenues in Multiple Myeloma
- Requirement for Map2k1 (Mek1) in Extra-Embryonic Ectoderm During Placentogenesis
- Kinases That Are Currently Stored in the Phospho.ELM Database
- Supplementary Table 2
- <I>MAP2K1</I> Mutation in a Patient with Langerhans Cell Histiocytosis
- List of Actionable Genes and Potential Matched Therapy
- Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity Johannes C
- The Mechanism of Tiaoganyipi Formula for Treating Chronic Hepatitis
- Supporting Information for “A High-Throughput Targeted Proteomic Approach for Comprehensive
- Biocarta and KEGG
- Lung Cancer and the MAP2K1 K57N Mutation
- Prevalence of Germline Mutations in Cancer Susceptibility Genes In
- A FRET Based High Content Screen Identifies DMPK As a Novel Tether of ER and Mitochondria
- Cdk5 Activity in the Brain – Multiple Paths of Regulation
- Stage-Dependent Expression of PI3K/Akt-Pathway Genes In
- Dissection of TBK1 Signaling Via Phosphoproteomics in Lung Cancer Cells